Nautilus Biotechnology (NAUT) Current Leases (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Current Leases data on file, last reported at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 9.19% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (down 9.19% YoY), and the FY2025 full-year result was $3.8 million, down 6.47% from the prior year.
• Current Leases advanced to $3.9 million in Q1 2026, from $3.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $4.2 million in Q1 2025 to a low of $1.5 million in Q1 2022.
• A 5-year average of $3.3 million and a median of $3.7 million in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases soared 419.75% in 2022 and declined 9.19% in 2026, its largest moves.
• Tracing NAUT's Current Leases over 5 years: stood at $2.0 million in 2022, then surged by 77.7% to $3.5 million in 2023, then increased by 15.8% to $4.1 million in 2024, then retreated by 6.47% to $3.8 million in 2025, then gained by 0.52% to $3.9 million in 2026.
• Business Quant data shows NAUT's Current Leases at $3.9 million in Q1 2026, $3.8 million in Q4 2025, and $4.2 million in Q3 2025.